Lung 18F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 185, Issue 6, 2012, Pages 670-679

  Marsboom, Glenn ^a   Wietholt, Christian ^a,b   Haney, Chad R ^a   Toth, Peter T ^a   Ryan, John J ^a   Morrow, Erik ^a   Thenappan, Thenappan ^a   Bache Wiig, Peter ^a   Piao, Lin ^a   Paul, Jonathan ^a   Chen, Chin Tu ^a   Archer, Stephen L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Visage Imaging Inc   (United States)

Author keywords

(HIF 1 ); Glucose transporter 1 (Glut1); Glycolysis; Hypoxia inducible factor 1 ; Imatinib; Sugen 5416

Indexed keywords

DICHLOROACETIC ACID; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; MONOCROTALINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MONITORING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; GLYCOLYSIS; HYPERTROPHY; HYPOXIA; LASER CAPTURE MICRODISSECTION; METABOLISM; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; REMISSION; SENSITIVITY ANALYSIS; SMOOTH MUSCLE FIBER; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; LUNG WEDGE PRESSURE; METHODOLOGY; MONITORING; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; REPRODUCIBILITY; SCINTISCANNING; SPRAGUE DAWLEY RAT;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FLUORODEOXYGLUCOSE F18; HYPERTENSION, PULMONARY; MONITORING, PHYSIOLOGIC; OXYGEN CONSUMPTION; POSITRON-EMISSION TOMOGRAPHY; PULMONARY WEDGE PRESSURE; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS;

EID: 84858180382     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201108-1562OC     Document Type: Article

References (35)

1. McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, Puttagunta L, Michelakis ED. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 2005;115:1479-1491. (Pubitemid 40814657)
2. Geraci MW, Moore M, Gesell T, Yeager ME, Alger L, Golpon H, Gao B, Loyd JE, Tuder RM, Voelkel NF. Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ Res 2001;88:555-562. (Pubitemid 32275790)
3. Thomas M, Docx C, HolmesAM, Beach S, Duggan N, England K, Leblanc C, Lebret C, Schindler F, Raza F, et al. Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline. Am J Pathol 2009;174:380-389.
4. Kouri FM, Queisser MA, Konigshoff M, Chrobak I, Preissner KT, Seeger W, Eickelberg O. Plasminogen activator inhibitor type 1 inhibits smooth muscle cell proliferation in pulmonary arterial hypertension. Int J Biochem Cell Biol 2008;40:1872-1882.
5. Zakrzewicz A, Hecker M, Marsh LM, Kwapiszewska G, Nejman B, Long L, Seeger W, Schermuly RT, Morrell NW, Morty RE, et al. Receptor for activated C-kinase 1, a novel interaction partner of type II bone morphogenetic protein receptor, regulates smooth muscle cell proliferation in pulmonary arterial hypertension. Circulation 2007;115:2957-2968. (Pubitemid 46912099)
6. Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998;101:927-934. (Pubitemid 28125268)
7. Hansmann G, de Jesus Perez VA, Alastalo TP, Alvira CM, Guignabert C, Bekker JM, Schellong S, Urashima T, Wang L, Morrell NW, et al. An antiproliferative BMP-2/PPARg/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest 2008;118:1846-1857. (Pubitemid 351632387)
8. Morrell NW, Yang X, Upton PD, Jourdan KB, Morgan N, Sheares KK, Trembath RC. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-b1 and bone morphogenetic proteins. Circulation 2001;104:790-795. (Pubitemid 32762677)
9. Bonnet S, Michelakis ED, Porter CJ, Andrade-Navarro MA, Thebaud B, Haromy A, Harry G, Moudgil R, McMurtry MS, Weir EK, et al. An abnormal mitochondrial-hypoxia inducible factor-1a-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 2006;113:2630-2641. (Pubitemid 43948012)
10. Fijalkowska I, Xu W, Comhair SA, Janocha AJ, Mavrakis LA, Krishnamachary B, Zhen L, Mao T, Richter A, Erzurum SC, et al. Hypoxia inducible-factor 1a regulates the metabolic shift of pulmonary hypertensive endothelial cells. Am J Pathol 2010;176:1130-1138.
11. Xu W, Koeck T, Lara AR, Neumann D, DiFilippo FP, Koo M, Janocha AJ, Masri FA, Arroliga AC, Jennings C, et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci USA 2007;104:1342-1347. (Pubitemid 46184006)
12. Michelakis ED, McMurtry MS, Wu XC, Dyck JR, Moudgil R, Hopkins TA, Lopaschuk GD, Puttagunta L, Waite R, Archer SL. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation 2002;105:244-250. (Pubitemid 34084326)
13. Sutendra G, Bonnet S, Rochefort G, Haromy A, Folmes KD, Lopaschuk GD, Dyck JR, Michelakis ED. Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension. Sci Translat Med 2010;2:44ra58.
14. + channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007;11:37-51.
15. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. Hif-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006;3:177-185.
16. Lu CW, Lin SC, Chen KF, Lai YY, Tsai SJ. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem 2008;283:28106-28114.
17. Archer SL, Marsboom G, Kim GH, Zhang HJ, Toth PT, Svensson EC, Dyck JR, Gomberg-Maitland M, Thebaud B, Husain AN, et al. Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation 2010;121:2661-2671.
18. Bowers R, Cool C, Murphy RC, Tuder RM, Hopken MW, Flores SC, Voelkel NF. Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med 2004;169:764-769. (Pubitemid 38338929)
19. Knoechel TR, TuckerAD, Robinson CM, Phillips C, TaylorW, Bungay PJ, Kasten SA, Roche TE, Brown DG. Regulatory roles of the N-terminal domain based on crystal structures of human pyruvate dehydrogenase kinase 2 containing physiological and synthetic ligands. Biochemistry 2006;45:402-415. (Pubitemid 43100407)
20. McMurtry MS, Bonnet S, Wu X, Dyck JR, Haromy A, Hashimoto K, Michelakis ED. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 2004;95:830-840. (Pubitemid 39390586)
21. Guignabert C, Tu L, Izikki M, Dewachter L, Zadigue P, Humbert M, Adnot S, Fadel E, Eddahibi S. Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22α-targeted overexpression of the serotonin transporter. FASEB J 2009;23:4135-4147.
22. 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379-387.
23. 18F]fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol. J Am Coll Cardiol 2005;45:1849-1855.
24. Piao L, Fang YH, Cadete VJ, Wietholt C, Urboniene D, Toth PT, Marsboom G, Zhang HJ, Haber I, Rehman J, et al. The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. J Mol Med 2010;88:47-60.
25. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297:L1013-L1032.
26. Ryan J, Bloch K, Archer SL. Rodent models of pulmonary hypertension: Harmonisation with the World Health Organisation's categorisation of human PH. Int J Clin Pract 2011;65:15-34.
27. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, Voelkel NF, Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001;15:427-438. (Pubitemid 32141434)
28. Urboniene D, Haber I, Fang YH, Thenappan T, Archer SL. Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2010;299:L401-L412.
29. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811-2821. (Pubitemid 41434408)
30. Frid MG, Brunetti JA, Burke DL, Carpenter TC, Davie NJ, Reeves JT, Roedersheimer MT, van Rooijen N, Stenmark KR. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol 2006;168:659-669. (Pubitemid 43271163)
31. Shimoda LA, Manalo DJ, Sham JS, Semenza GL, Sylvester JT. Partial HIF-1α deficiency impairs pulmonary arterial myocyte electrophysiological responses to hypoxia. Am J Physiol Lung Cell Mol Physiol 2001;281:L202-L208.
32. 18FDG uptake and expression of glucose transporter-1 and hexokinase II between low and high-risk tumors: preliminary study. Eur J Radiol 2012;81:146-151.
33. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of Glut1 mRNA by hypoxia-inducible factor-1: interaction between h-Ras and hypoxia. J Biol Chem 2001;276:9519-9525.
34. Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010;121:2045-2066.
35. Mizuno S, Bogaard HJ, Kraskauskas D, Alhussaini A, Gomez-Arroyo J, Voelkel NF, Ishizaki T. p53 gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice. Am J Physiol Lung Cell Mol Physiol 2011;300:L753-L761.